126533-37-7

Upstream product

• 5398-36-7 2-aminothiazole-4-carboxylate 
• 76-83-5 trityl chloride 

Downstream Products

• 288590-32-9 1,2,3-benzotriazol-1-yl 2-triphenylmethylamino-1,3-thiazole-4-carboxylate 
• 126533-38-8 2-tritylaminothiazole-4-methanol 
• 288590-38-5 ethyl 2-[2-[2-[2-(triphenylmethylamino)-1,3-thiazole-4-carboxamido]-1,3-thiazole-4-carboxamido]-1,3-thiazole-4-carboxamido]-1,3-thiazole-4-carboxylate 
• 288590-37-4 ethyl 2-[2-[2-(triphenylmethylamino)-1,3-thiazole-4-carboxamido]-1,3-thiazole-4-carboxamido]-1,3-thiazole-4-carboxylate 
• 288590-36-3 ethyl 2-[2-(triphenylmethylamino)-1,3-thiazole-4-carboxamido]-1,3-thiazole-4-carboxylate 
• 139355-13-8 2-triphenylmethylamino-4-carboxy-1,3-thiazole 

Relevant academic research and scientific papers

Inhibition of HIV-1 integrase-catalysed reaction by new DNA minor groove ligands: The oligo-1,3-thiazolecarboxamide derivatives

Human immunodeficiency virus type 1 (HIV-1) integrase (IN) is an essential enzyme in the life cycle of the retrovirus, responsible for catalysing the insertion of the viral genome into the host cell chromosome. For this reason it provides an attractive target for antiviral drug design. We synthesized a series of novel thiazole (Tz)-containing oligopeptides (TCOs; oligo-1,3-thiazolecarboxamides), specifically interacting within the minor groove of DNA. The oligocarboxamide derivatives contained 1-4 Tz rings and different N- and C-terminal groups. The effect of these oligocarboxamides on the HIV-1 IN-catalysed reaction was investigated. Some of the compounds were able to inhibit the reaction. The inhibitory effect of the TCOs increased with the number of Tz units. The structure of various additional positively and/or negatively charged groups attached to the N- and C-termini of TCOs had a pronounced effect on their interaction with the DNA substrate complexed to IN. Modified TCOs having a better affinity for this complex should provide a rationale for the design of drugs targeting the integration step. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof

A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the

Thiazole derivatives, their preparation and their use in the treatment of diabetes complications

Compounds of formula (I): STR1 in which: R1 and R2 are independently hydrogen, alkyl, aliphatic hydrocarbon groups having one or two carbon-carbon double or treble bonds, cycloalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, alkanoyl, alkenyol, cycloalkylcarbonyol, arylcarbonyl, substituted arylcarbonyl, arylalkanoyl, substituted arylalkanoyl, arylalkenoyl, substituted arylalkenoyl, alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, aralkyloxycarbonyl, substituted aralkyloxycarbonyl, optionally substituted carbamoyl or thiocarbamoyol, alkylsulfonyl, haloalkylsulfonyl, arylsulfonyl, substituted arylsulfonyl, alkylthio, arylthio and substituted arylthio, or R1 and R2, together with the nitrogen atom to which they are attached, form a nitrogen-containing heterocyclic group; one of Ra and Rb is hydrogen, alkyl or halogen, and the other of Ra and Rb is a group of formula (II): STR2 R4 is hydrogen, carboxy, protected carboxy or optionally substituted carbamoyl; R5 is hydrogen, or carboxyalkyl or protected carboxyalkyl in which the alkyl part is C1 -C6 ; n=0, 1 or 2; X is oxygen or sulfur; are useful in the treatment of the complications attendant upon diabetes and may be prepared by condensation of a thiazolidine or rhodanine compound with a compound corresponding to the remainder of the molecule of the compound of formula (I).